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Abstract
Background: Stereotactic ablative body radiotherapy (SABR) is emerging as a non-invasive method for precision
irradiation of lung tumours. However, the ideal dose/fractionation schedule is not yet known. The primary purpose
of this study is to assess safety and efficacy profile of single and multi-fraction SABR in the context of pulmonary
oligometastases.
Methods/Design: The TROG 13.01/ALTG 13.001 clinical trial is a multicentre unblinded randomised phase II study.
Eligible patients have up to three metastases to the lung from any non-haematological malignancy, each < 5 cm in
size, non-central targets, and have all primary and extrathoracic disease controlled with local therapies. Patients are
randomised 1:1 to a single fraction of 28Gy versus 48Gy in four fractions of SABR. The primary objective is to assess
the safety of each treatment arm, with secondary objectives including assessment of quality of life, local efficacy,
resource use and costs, overall and disease free survival and time to distant failure. Outcomes will be stratified by
number of metastases and origin of the primary disease (colorectal versus non-colorectal primary). Planned substudies
include an assessment of the impact of online e-Learning platforms for lung SABR and assessment of the effect of
SABR fractionation on the immune responses. A total of 84 patients are required to complete the study.
Discussion: Fractionation schedules have not yet been investigated in a randomised fashion in the setting of
oligometastatic disease. Assuming the likelihood of similar clinical efficacy in both arms, the present study design
allows for exploration of the hypothesis that cost implications of managing potentially increased toxicities from
single fraction SABR will be outweighed by costs associated with delivering multiple-fraction SABR.
Trials registration: ACTRN12613001157763, registered 17th October 2013
Keywords: SBRT, SABR, Metastases, Lung, Cost effectiveness, Quality of life
* Correspondence: shankar.siva@petermac.org
1Peter MacCallum Cancer Centre, 2 St Andrews Place, East Melbourne 3002,
Australia
2University of Melbourne, Royal Parade, Parkville 8006, Australia
Full list of author information is available at the end of the article
© 2016 Siva et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Siva et al. BMC Cancer  (2016) 16:183 
DOI 10.1186/s12885-016-2227-z
Background
SABR is emerging as a non-invasive method for preci-
sion irradiation of pulmonary oligometastases using
radioablative doses with a higher biological effect than
can be achieved with conventional radiotherapy. The
paradigm of aggressive local treatment with SABR for
oligometastatic disease is well recognised [1–3]. Stereo-
tactic body ‘radiosurgery’ (SRS) refers to the accurate de-
livery of a single precise, large and highly conformal
SABR treatment. Multi-fraction SABR and single frac-
tion SABR represent a radical departure from classical
fractionated radiotherapy. A previous systematic review
[4] of SABR for secondary lung cancers performed in
2010 revealed 154 patients treated with single fraction
SABR and 343 patients treated with fractionated SABR.
In the single fraction experience, the mean weighted
2 year local control was 78.6 % (range 48–91 %) and
2 year overall survival was 50.3 % (range, 33–73 %). The
rate of significant toxicity (grade 3 or higher) was only
3.3 %. The results are comparable in the fractionated
SABR series. The 2-year weighted local control was
77.9 % (range, 67–96 %). The corresponding 2-year
weighted overall survival was 53.7 % (range 33–89 %),
with a 4 % rate of grade 3 or higher radiation toxicities.
These outcomes are comparable with surgical alterna-
tives, with low rates of significant toxicity.
Stereotactic radiotherapy is a rapidly evolving tech-
nique that has been implemented widely through Eur-
ope, North America and Japan. A survey of 1600
American radiation oncologists showed that 64 % of
physicians used SABR (95 % confidence interval, 60–
68 %), of whom nearly half adopted it in 2008 or later
[5]. Lung was the most popular site of SABR use (89 %),
with the three and four fraction SABR schemes account-
ing for 68 % of prescribed treatments. In contradistinc-
tion the single fraction approach is commonly employed
by several institutions in Europe [6–10]. Similarly in the
Australian context several dose-fractionation schedules
have been developed. For example the Peter MacCallum
Cancer Centre in Victoria has reported the use of a sin-
gle fraction technique [11], whereas the Northern Syd-
ney Cancer Centre have implemented a four fraction
SABR approach in New South Wales. A retrospective
comparison of these two approaches indicated no signifi-
cant differences in clinical outcomes between single or
multi-fraction approaches [12].
The primary purpose of this study is to compare single
versus multi-fraction SABR in the context of pulmonary
oligometastases. The proposed investigational fraction-
ation schedules in the SAFRON phase II study are 28Gy
in one fraction versus 48Gy in four fractions of SABR.
Both fractionation schedules have been previously used
in the context of lung metastases [4]. Comparing these
arms using the biological effective dose (BED) calculation
[13], it is apparent that these fractionation schedules are
very similar for tumour effects (Table 1). Both arms de-
liver biological effective doses above 100Gy to the periph-
ery of the target, which is known to correlate with very
high rates of local control in the order of ~90 % [6, 10,
14]. A single fraction SABR is theoretically as effective as
four-fraction SABR and is more convenient for the patient
and has the potential to be more cost-effective. However
the BED calculations (Table 1) suggest that there is a po-
tential for greater late tissue toxicity from this approach.
Theoretically, much of this potential toxicity is mitigated
by highly accurate radiation delivery; nevertheless, there is
clear clinical and theoretical equipoise to support the de-
sign of this trial.
Methods/Design
Study design
This study is lead by the TransTasman Radiation Oncol-
ogy Group (TROG) in collaboration with the Australa-
sian Lung Cancer Trials Group (ALTG). The TROG
13.01/ALTG 13.001 SAFRON II study is a multi-
institutional randomised interventional phase II clinical
trial. The study has ethics board approval from the Peter
MacCallum Cancer Centre (HREC/14/PMCC/2), and is
registered on www.clinicaltrials.gov (ID: NCT01965223).
All participating centres will obtain ethical approval
prior to study activation. The study population are pa-
tients with oligometastases (1–3 metastases) to the lung
(from any non-haematological malignancy). The trial
schema can be found in Fig. 1. The intervention for
ARM 1 is single fraction SABR - 28Gy delivered in one
fraction. The intervention for ARM 2 is multi-fraction
SABR - 48Gy delivered in four fractions, delivered over
2 weeks, with each fraction on non-consecutive days.
Table 2 outlines dose constraints. Follow-up clinical
visits including surveillance CT scanning will occur 3
monthly for year 1, 4 monthly for year 2, and thereafter
6 monthly until year 5 after treatment delivery. Written
informed consent will be obtained from all individuals
for participation in this study.
The primary endpoint is safety of SABR treatment as
measured by the incidence of grade 3 and 4 toxicities
measured using CTCAE V4.0 within 12 months of treat-
ment completion. Key secondary endpoints include a)
Quality of life using EQ-5D and MDASI-LC, b) Local ef-
ficacy (time to local failure), c) Resource use and costs
associated with treatment, d) Other clinical outcomes
Table 1 BED calculations
Arm (1): 28Gy in 1# Arm (2): 48Gy in 4#
Early (tumour) effects α/β = 10 106Gy 105Gy
Late (tissue) effects α/β = 3 289Gy 240Gy
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(overall survival, time to distant failure and disease free
survival).
Inclusion/exclusion criteria
Patients may be included in the trial only if they meet all
of the following key inclusion criteria at randomisation:
 Aged 18 years or older
 ECOG 0–1 inclusive
 A maximum of three metastases to the lung from
any non-haematological malignancy
 Individual tumour diameter ≤ 5 cm. Targets are located
away from central structures (defined as 2 cm beyond
bifurcation of lobar bronchi and central airways)
o Note: Targets in proximity to chest wall and
mediastinum that meet these inclusion criteria are
eligible
 Primary and extrathoracic disease controlled with
local therapy (e.g. surgery/definitive radiotherapy)
Key exclusion criteria are listed below:
 Previous high-dose thoracic radiotherapy in region
of proposed SABR, as defined as a BED10 of 40Gy
 Cytotoxic chemotherapy within 3 weeks of
commencement of or concurrently with treatment
o Hormonal manipulation agents are allowable
concurrently with treatment (e.g. aromatase
inhibitors, selective oestrogen receptor
modulators, and gonadotrophin releasing hormone
receptor modulators)
 Concurrent targeted agents (such as sunitinib,
bevacizumab and tarceva) are not allowed
 It is recommended that targeted agents not be
delivered within 7 days of delivery of radiation
therapy treatment
 Germ cell and small cell carcinoma histologies
Statistical considerations
This study is a randomised controlled phase II multicen-
tre trial, with the main objective to determine whether
Fig. 1 Study flowchart




Constraint 28Gy in 1# 48Gy in 4#/2wks
Normal Lungs V5 < 1000 cc 66 % 7.4Gy 66 % 12.4Gy, (max 3.1Gy per fraction)
Heart Heart Maximum dose (0.03 cc) < 15 cc 22Gy 34 Gy, (max 8.5 Gy per fraction)
16Gy 28 Gy, (max 7 Gy per fraction)
Oesophagus Oesophagus Maximum dose (0.03 cc) 15.4Gy 30Gy, (max 7.5Gy per fraction)
Spinal Cord SpinalCord Maximum dose (0.03 cc) 12Gy 20.8Gy, (max 5.2Gy per fraction)
Brachial plexus BrachialPlexus Maximum dose (0.03 cc) 15Gy 24Gy, (max 6Gy per fraction)
Skin (5 mm subcutis) Skin Maximum dose (0.03 cc) < 10 cc 26Gy 36 Gy, (max 9 Gy per fraction)
23Gy 33.2 Gy, (max 8.3 Gy per fraction)
Chest walla ChestWall <70 cc b26Gy to full thickness 30Gy
Great Vessels GreatVessel Maximum Dose (0.03 cc) 30 Gy 49 Gy, (max 12.25 Gy per fraction
Liver Liver V20, V30 No constraint, but dose/volume
parameters to be documented
No constraint, but dose/volume
parameters to be documented
aChest wall dose limit may be exceeded if rib structure lies close to or in contact with the PTV
b26Gy isodose line should not cross full thickness of the chest wall structure
Definitions: Vx describes the volume that receives xGy, e.g. V5 < 66 % represents that the volume of specified OAR receiving 5 Gy shall be less than 66 %
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single fraction radiosurgery (28Gy/1) or fractionated
SABR (48Gy/4) has acceptable toxicity for the treatment
of pulmonary oligometastases, as defined by a maximum
acceptable toxicity rate of grade 3 or higher adverse
events of < 5 %.)
If both treatments have acceptable toxicity profile the
criteria for selecting which arm will be used in the phase
III trial is as follows:
a) The arm with superior clinical outcomes will be
chosen, based on time to local failure and overall
survival.
b) If there is no significant difference in clinical
outcomes, the arm with the superior quality of life
will be chosen.
c) If there is no significant difference in quality of life,
the arm associated with the least amount of
resource use will be chosen.
Statistical analysis
Toxicities will be summarised as counts and percentages
and presented in tabular form. The rate of grade 3 or
higher toxicities at 1 year will be estimated for each arm
by two methods. The first method (primary analysis) will
evaluate the toxicities for participants who complete
1 year of follow up with 80 % confidence interval assum-
ing binomial distribution. The second method (sensitiv-
ity analysis) will estimate the toxicities using cumulative
incidences with death as a competing event. Time to
event outcomes will be described using Kaplan-Meier
methods with 95 % confidence intervals for each arm.
The curves will be compared between arms using the
Logrank test.
Overall Health-Related Quality of Life (HRQOL) will
be measured using the MDASI-LC, a 22 item QoL mod-
ule with three specific lung cancer questions. The results
will be analysed using general linear mixed models. The
area under the curve (AUC) will be compared between
the arms using linear contrasts from the general linear
mixed model. The linear mixed model will include arm,
time and the interaction between arm and time as fixed
effects with patients as random effect. Baseline MDASI-
LC will be included as a covariate in the model. Comple-
tion rate of MDASI-LC at each time point will be re-
ported in tabular form.
Health economics: assessment of quality of life
For the purposes of the economic evaluation, HRQOL
will be assessed using the EQ5D-5 L, a validated self-
completed multi-attribute utility measure which will be
used to estimate Quality adjusted life years (QALYs) for
use the economic evaluation [15, 16]. This 5 item scale
covers the following dimensions: mobility, self-care,
usual activities, pain/discomfort and anxiety/depression,
with each dimension having five levels. Participants will
complete both measures at baseline and during follow-
up.
Health economics: assessment of resource use and costs
The direct resources associated with the delivery of
SABR will be measured by observing the health care
professional time and consumables required to plan and
deliver of the radiotherapy intervention; an average cost/
fraction will be calculated, reflecting Australian equip-
ment and practice. Patient costs will be measured in
terms of travel time and clinic time (i.e. time away from
usual activities). Any visits to Emergency Departments
or admissions to hospital will be captured directly from
hospital records. Consent will be obtained from partici-
pants to access their Medicare Benefits Scheme (MBS)
and Pharmaceutical Benefits Scheme (PBS) claims
through Medicare (or appropriate national health ad-
ministration) in order to capture any ancillary health ex-
penses not costed directly to the primary cancer hospital
provider. Hospital-specific costs and market prices are
likely to be available for most of the resource items (e.g.
MBS-fees). In the absence of market prices, data from
the literature and expert opinion will be used to estimate
unit prices. Results will be presented as total health care
(by type) used, cost per unit of health care (e.g. PBS
price) and total cost of health care used over the period
of the trial and follow-up (3-years).
Health economics analysis
The results of the economic evaluation will be reported
as net costs and benefits for ARM 1 versus ARM 2. The
costs of each ARM will take into account any cost-
savings due to avoided health care utilisation and/or tox-
icities. Mean estimates of costs will be used and confi-
dence intervals will be generated by boot-strapping the
data. Benefits will be measured via the EQ5D5L ques-
tionnaire. Results will be presented in terms of the incre-
mental cost-effectiveness ratio (ICER) as a cost/QALY
gained. The incremental QALY will represent the im-
provement in quality of life between ARM 1 and ARM
2. The robustness and validity of the cost-effectiveness
analysis will be explored using probabilistic sensitivity
analysis.
Sample size calculation
The maximum acceptable toxicity rate (grade 3 or
higher adverse events) is considered to be 5 %. The de-
sired upper limit of the 80 % confidence interval for a
true toxicity rate of 5 % is 17 %. For a one-sided exact
test for proportion with alpha = 0.1 and 80 % power, the
required sample size is 38 evaluable patients for each
arm of the trial. Assuming that up to 8 % of participants
Siva et al. BMC Cancer  (2016) 16:183 Page 4 of 8
may be considered ineligible/unanalysable, 42 partici-
pants will be recruited in each arm.
Facilitating multicentre implementation of SABR through
an online e-Learning platform
Online platforms are useful tools for teaching, training
and education of health care professionals. There are a
limited number of studies examining web-based training
for radiation oncology clinicians [17, 18]. There has also
been description of how to design a radiation oncology
curriculum for e-Learning [19]. Prior to this study, there
has been only one previous report of the use of e-
Learning to support advanced image guided multi-
centre radiotherapy trials [20]. As part of the TROG
13.01/ALTG 13.001 study, radiation therapists (RT),
radiation oncologists (RO) and radiation oncology medical
physicists (ROMP) are required to complete an e-
Learning package to facilitate the safe and effective deliv-
ery of SABR to the lung. The e-Learning material covered
7 modules: Clinical Background, Organs-at-risk Contour-
ing, Planning Technique & Evaluation, plan optimisation,
Patient Specific Quality Assurance, 4DCT Simulation and
CBCT & Image Guidance. The modules were created by a
multi-disciplinary team consisting of radiation oncologists
(RO), radiation therapists (RT), diagnostic radiologists and
medical physicists (ROMP). As part of the credentialing
processit was a requirement for RT, RO and ROMP to
complete a subset ofcore modules that were specific to
their profession (listed in Table 3). There were no
requirements to complete non-core modules however
these were available for participants to complete. The ob-
jective of this study platoform was to improve confidence
and increase operator knowledge in lung SABR through
the use of pre- and post-test assessment as well as long-
term retention assessment.
Translational substudies
Out-of-field tumour regression (the Abscopal effect) is a
known systemic effect of radiation in the preclinical and
clinical setting [21, 22]. Direct ionising radiation elicits
innate immune recognition of tumour, in the absence of
a pathogen, through the liberation of cellular stress sig-
nals collectively termed, “danger signals” [23, 24]. The
primary driver of increased immune mediated cell death
is an enhanced capacity to recognise and mount an
adaptive immune response to the established tumour.
Three molecular signals are primarily responsible: the
promotion of uptake of dying cells by dendritic cells
(DCs), the cross-presentation of tumour-derived anti-
gens to T cells and the activation of anti-tumour T cells
[25]. These responses provide tools for improved rec-
ognition and killing by tumour-antigen reactive T cells
[26]. There is presently no clinical data in humans
assessing the effects of fractionation in ablative radio-
therapy. As part of this study, peripheral blood mono-
nuclear cells will be collected in a subset of patients
prior to and after delivery of SABR. Where possible,
pre and post-treatment tumour biopsy will be per-
formed in this subset. A comprehensive characterisa-
tion of lymphocyte populations residing within the
tumour bed and peripheral blood is planned. In
addition to the planned substudy assessing immune
effects of SABR, trial datasets will be available for
secondary analysis of post-hoc technical and clinical
objectives through TROG.
Discussion
SABR is a non-invasive alternative treatment option that
is presently available for a variety of pulmonary malig-
nancies. In the setting of primary NSCLC, it has been
postulated that SABR may be more desirable in patients
with pre-existing comorbidities and the elderly [27]. In-
deed, controlled non-randomised series also suggest
SABR may be a valid approach in patients considered
operable with similar outcomes to surgery in Stage I
NSCLC [28]. More recently, the combined results of the
ROSEL and STARS randomised clinical studies demon-
strates clinical outcomes from SABR that compare
favourably with surgery with fewer associated toxicities
in operable patients with stage I NSCLC [29]. However,
it is unclear at present what the ideal approach for dose/
fractionation should be in the setting of primary NSCLC.
The RTOG 0915 study demonstrated comparable clin-
ical outcomes of a single fraction of 34 Gy approach in
comparison to 48Gy delivered over four fractions [30].
There was a pre-stated plan for comparison with the
standard of 54 Gy in 3 fractions used in the United
States for stage I NSCLC, however this phase III study
may not eventuate.
The management of patients with distant metastases
from solid tumours is usually conducted with palliative
intent. On analysis of the Surveillance, Epidemiology,
and End Results (SEER) database, the 5-year survival of
patients with metastatic disease of common malignan-
cies such as colorectal, breast and lung cancer was 7, 19
Table 3 e-Learning module description and discipline-specific
‘core modules’ allocated for completion
Modules RO RT ROMP
Clinical Background ✓ ✓ ✓
Contouring Organs-at Risk (not included in the tests)
Planning Technique & Evaluation ✓ ✓
Planning Optimisation ✓ ✓
Patient Specific QA (not included in the tests) ✓
4DCT Simulation ✓ ✓
CBCT & Image Guidance ✓ ✓ ✓
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and 2 % respectively [31]. Treatment predominantly in-
volves palliative chemotherapy to address widespread
disease without expectation of long-term survival. In
contrast, Hellman and Weichselbaum hypothesised the
existence of an intermediate state between widespread
metastatic disease and locally confined disease and
coined the term “oligometastasis” [1]. In this setting, tar-
geted therapies have procured significant long-term sur-
vival. Surgical resection has been shown in a randomised
trial to increase median survival in patients with single
brain metastases from 15 weeks to 40 weeks (p = 0.01)
[32]. Systematic reviews of the resection of hepatic me-
tastases show a 5-year survival of 25–30 % [33, 34].
Pulmonary tissue represents a common site for meta-
static seeding. A multinational registry of 5206 patients
undergoing surgical resection of lung metastases showed
a 5-year survival rate of 36 %, with the median survival
being 35 months [35]. All these results are remarkable
given the typically poor survival for patients with meta-
static tumours, and may justify an aggressive approach
for patients with ‘oligometastatic’ disease. However,
metastasectomy can be associated with significant risk of
patient morbidity and the cost-effectiveness of such an
approach is currently unknown.
Very little is known regarding the costs, quality of life
or QALY outcomes secondary to SABR in the setting of
pulmonary metastatic disease. Shared decision-making is
now advocated as the preferred model of treatment
planning [36]. In order to make informed treatment de-
cisions, patients and clinicians need to know possible ad-
verse effects on quality of life; particularly if the patient
has considerable co-morbidities as is commonly the case
in an ageing population. Given the explosion of trials
internationally investigating SABR, it is surprising that
there has been little effort to formally assess quality of
life outcomes of SABR. As the primary objective is to
determine whether SABR can be delivered safely with
minimal toxicity, the participants in this trial rando-
mised to a single fraction treatment may perceive that
the benefit of faster, convenient treatment delivery
comes at the cost of an increased likelihood of sustain-
ing toxicity. However, expected toxicities are low in
comparison to surgical lung resection, where rib spread-
ing procedures result in up to 44 % of patients suffering
pain longer than 6 months after surgery [37] and ap-
proximately 30 % of patients suffering chronic pain be-
yond 5 years after surgery [38]. Hence, less arduous
SABR treatment techniques with expected high levels of
cancer control are likely to produce low levels of psycho-
logical distress, particularly anxiety. This information
may be used to inform the design of future randomised
phase III studies.
The full immunological potential of radiotherapy may
be influenced by the dose and fractionation of radiation
employed, for both single fraction and fractionated ap-
proaches [39]. Ablative dose ranges employed by SABR
heralds a potential for even greater augmentation of the
tumouricidal immune response than conventional radio-
therapy [40]. Ablative doses result in a greater degree of
stromal-vascular damage, ceramide-induced endothelial
cell damage which may result in complete inhibition of
tumour re-vascularisation and increased apoptosis of
tumour cells [41–43]. Immunogenic responses at sites
distant to the SABR therapy have already been reported
by our group [44] and others [45]. It is unclear, however,
whether single fraction or hypofractionated radiotherapy
is optimal in eliciting immune responses. For example,
significant cross-priming of T-cells against tumour anti-
gens have been demonstrated to be induced by a single
dose of 15Gy in the draining lymph nodes [46]. Our
group at the Peter MacCallum Cancer Centre identified
that single dose (12Gy) radiotherapy did not deplete
established tumours of effector cells critical to the anti-
tumour activity with enrichment of functionally active,
tumour-specific T-cells [47]. This is similar to a recent
demonstrating that single fraction of 30Gy to tumour re-
sulted in an intense activated T cell tumour infiltrate,
and a loss of myeloid derived suppressor cells [48]. Sin-
gle fraction ablative RT has also been shown to synergise
with the T-cell checkpoint inhibitor anti-PD-1 in murine
models allowing for induction of an anti-tumour im-
mune response by relief of tumour-mediated immuno-
suppression [49–51]. On the other hand, reports from
New York University suggest that 3 × 8Gy hypofractio-
nated radiotherapy results in enhanced immunogenicity
in direct comparison to single fraction ablation [52, 53].
The translational component of this study aims to help
better define the innate immune response evoked by dif-
ferent fractionation schedules of SABR and to investigate
the prognostic implications of these changes. In the fu-
ture this research may help to define strategies for com-
bining immunotherapy to maximise patient outcomes
after SABR.
Fractionation schedules have not been investigated in
a randomised fashion to date in the setting of oligometa-
static disease. From a philosophical perspective, use of
the fewest possible treatments whilst maintaining clinical
effectiveness is critical in this cohort of patients given
the significant competing risks of distant disease recur-
rence. The present design allows for exploration of the
hypothesis that cost implications of managing increased
toxicities from single fraction SABR may be outweighed
by costs associated with multiple-fraction SABR, with
the assumption of similar clinical efficacy in both arms.
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